NCT05299866

Brief Summary

This randomized controlled trial is designed to investigate the effect of low-dose of S-ketamine combined with sufentanil for postoperative patient-controlled intravenous analgesia in patients following cesarean section.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
216

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Apr 2022

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 26, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

March 29, 2022

Completed
14 days until next milestone

Study Start

First participant enrolled

April 12, 2022

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2024

Completed
Last Updated

February 28, 2023

Status Verified

February 1, 2023

Enrollment Period

2.1 years

First QC Date

February 26, 2022

Last Update Submit

February 25, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • The percentage of patients with moderate-to-severe pain

    Moderate-to-severe pain is defined as a numeric rating scale (NRS; an 11-point scale where 0=no pain and 10=the worst pain) pain score ≥4.

    Up to 48 hours after surgery

Secondary Outcomes (1)

  • NRS pain score at rest and with movement

    Hour 12 & Hour 24 & Hour 48 after surgery

Other Outcomes (4)

  • The total number of presses of Patient-controlled Analgesia (PCA)

    Up to 48 hours after surgery

  • The percentage of using rescue analgesics

    Up to 48 hours after surgery

  • The Richmond Agitation-Sedation Scale(RASS)

    Hour 12 & Hour 24 & Hour 48 after surgery

  • +1 more other outcomes

Study Arms (2)

S-ketamine group

EXPERIMENTAL

The pump is established with S-ketamine 1mg/kg, sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml.

Drug: S-ketamine

Control group

PLACEBO COMPARATOR

The pump is established with sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml.

Drug: Placebo

Interventions

After surgery, patient-controlled analgesia is provided. The pump is established with S-ketamine 1mg/kg, sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml. The pump is programmed to deliver 2 ml boluses with a background infusion rate at 2 ml /h and a 30 min lockout interval.

S-ketamine group

After surgery, patient-controlled analgesia is provided. The pump is established with sufentanil 2microgram/kg, andondansetron16mg, diluted with normal saline to 100 ml. The pump is programmed to deliver 2 ml boluses with a background infusion rate at 2 ml /h and a 30 min lockout interval.

Control group

Eligibility Criteria

Age20 Years - 40 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • American Society of Anesthesiologists (ASA) physical status II
  • Patients aged between 20 and 40 years
  • kg/m² ≤BMI≤30 kg/m²
  • singleton term pregnancy
  • scheduled for elective cesarean section

You may not qualify if:

  • Refused to participant in this trial
  • Severe heart dysfunction or pulmonary insufficiency
  • Poor blood pressure control in those with hypertension (BP \>160/100 mmHg in the ward)
  • Previous history of Intracranial hypertension or hyperthyroidism
  • Previous history of schizophrenia, epilepsy, myasthenia gravis or delirium
  • Allergy to drugs used in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University

Jinan, Shandong, 250000, China

RECRUITING

Related Publications (4)

  • Brinck EC, Tiippana E, Heesen M, Bell RF, Straube S, Moore RA, Kontinen V. Perioperative intravenous ketamine for acute postoperative pain in adults. Cochrane Database Syst Rev. 2018 Dec 20;12(12):CD012033. doi: 10.1002/14651858.CD012033.pub4.

    PMID: 30570761BACKGROUND
  • Schwenk ES, Viscusi ER, Buvanendran A, Hurley RW, Wasan AD, Narouze S, Bhatia A, Davis FN, Hooten WM, Cohen SP. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018 Jul;43(5):456-466. doi: 10.1097/AAP.0000000000000806.

    PMID: 29870457BACKGROUND
  • Isik Y, Dag ZO, Tulmac OB, Pek E. Early postpartum lactation effects of cesarean and vaginal birth. Ginekol Pol. 2016;87(6):426-30. doi: 10.5603/GP.2016.0020.

    PMID: 27418219BACKGROUND
  • Hobbs AJ, Mannion CA, McDonald SW, Brockway M, Tough SC. The impact of caesarean section on breastfeeding initiation, duration and difficulties in the first four months postpartum. BMC Pregnancy Childbirth. 2016 Apr 26;16:90. doi: 10.1186/s12884-016-0876-1.

    PMID: 27118118BACKGROUND

MeSH Terms

Conditions

Agnosia

Interventions

Esketamine

Condition Hierarchy (Ancestors)

Perceptual DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Ling Dong, Ph.D

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
clinical professor

Study Record Dates

First Submitted

February 26, 2022

First Posted

March 29, 2022

Study Start

April 12, 2022

Primary Completion

May 31, 2024

Study Completion

June 30, 2024

Last Updated

February 28, 2023

Record last verified: 2023-02

Data Sharing

IPD Sharing
Will not share

Locations